Skip to main content

Table 1 Baseline characteristics by metformin use subgroup, based on pooled SUSTAIN 6 and PIONEER 6 data

From: Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6

  Metformin No-metformin P-value
Randomized, N (%) 4881 1599  
Age, years 64.8 (7.0) 67.1 (7.9)  < 0.0001
Female, n (%) 1718 (35.2) 584 (36.5) 0.3366
Prior cardiovascular event, n (%) 2190 (44.9) 694 (43.4) 0.3060
Prior heart failure, n (%) 852 (17.5) 313 (19.6) 0.0555
Diabetes duration, years 13.8 (8.0) 16.0 (9.2)  < 0.0001
HbA1c, % 8.4 (1.5) 8.6 (1.6)  < 0.0001
HbA1c, mmol/mol 68.1 (16.8) 70.5 (17.6)  < 0.0001
eGFR, mL/min/1.73 m2 79.4 (19.5) 61.9 (23.8)  < 0.0001
eGFR < 60 mL/min/1.73m2, n (%) 880 (18.0) 819 (51.2)  < 0.0001
Albuminuria, n (%)a 855 (36.0) 449 (51.9) N/A
Concomitant insulin use, n (%) 2351 (48.2) 1130 (70.7)  < 0.0001
TZD use, n (%) 129 (2.6) 65 (4.1)  < 0.0001b
Sulfonylurea, n (%) 1978 (40.5) 459 (28.7)  < 0.0001
DPP-4i, n (%) 5 (0.1) 2 (0.1)  < 0.0001
Body weight, kg 90.8 (20.3) 93.6 (22.5) 0.0002
BMI, kg/m2 32.3 (6.1) 33.2 (7.0) 0.0004
Diastolic BP, mmHg 76.8 (9.9) 75.7 (10.4)  < 0.0001
Systolic BP, mmHg 135.4 (17.1) 136.2 (18.2) 0.1289
Heart rate, bpm 71.8 (11.2) 70.7 (10.9) 0.0015
LDL-cholesterol, mmol/L 2.2 (0.9) 2.4 (0.9)  < 0.0001
LDL-cholesterol, mg/dL 85.6 (35.2) 91.7 (36.1)  < 0.0001
ACEis, n (%) 2304 (47.2) 680 (42.5) 0.3541c
ARBs, n (%) 1800 (36.9) 570 (35.6) 0.3541c
Statin, n (%) 3798 (77.8) 1200 (75.0) 0.0229d
  1. Data are mean (SD) unless stated otherwise
  2. aAlbuminuria percentage is calculated based on number of subjects with a urinary albumin-to-creatinine ratio measurement at baseline (only available for SUSTAIN 6)
  3. bP-value for interaction between different blood glucose-lowering medication, which included TZDs and other classes of medications
  4. cP-value for interaction between different anti-hypertensive therapy, which included ACEis, ARBs and other classes of medications
  5. dP-value for interaction between different lipid-lowering medications, which included statins and other classes of medications
  6. ACEi angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, BMI body mass index, BP blood pressure, DPP-4i dipeptidyl peptidase-4 inhibitor, eGFR estimated glomerular filtration rate, HbA1c glycated hemoglobin, LDL low-density lipoprotein, N/A not available, SD standard deviation, TZD thiazolidinedione
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840